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SUMMARY
Research on captive chimpanzees incurs considerable animal welfare, ethical and
financial costs. Advocates of such research claim these costs are outweighed by
substantial advancements in biomedical knowledge, and that the genetic similarity of
chimpanzees to humans enables the former to make critical contributions to
preventing, diagnosing and combating human diseases. To assess these claims, we
examined the disciplines investigated in 749 studies of captive chimpanzees published
from 1995-2004 inclusive, and subjected 95 randomly selected papers to a detailed
citation analysis:
49.5% (47/95) of papers had not been cited at the time of this study; 38.5% (34/95)
were cited by 116 papers that did not describe well-developed methods for combating
human diseases; 14.7% (14/95) of these chimpanzee studies were cited by (a total of
27) papers describing well-developed prophylactic, diagnostic or therapeutic methods
for combating human diseases. Close examination of these 27 human medical papers
revealed that in vitro research, human clinical and epidemiological investigations,
molecular assays and methods, and genomic studies, contributed most to their
development. Duplication of human outcomes, inconsistency with other human or
primate data, and other causes resulted in the absence of any chimpanzee study
demonstrating an essential contribution, or, in most cases, even a significant
contribution of any kind, towards the development of the described human treatment.
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INTRODUCTION
In a recent plea for increased research on captive chimpanzees, VandeBerg and Zola
(VandeBerg and Zola 2005) asserted in Nature that, “Many advances from biomedical
research with chimpanzees have been published in the past one to two years,
demonstrating that rapid medical progress pertinent to a wide range of human
diseases is being made through the use of chimpanzees.”
Claims such as these, made particularly by many researchers that currently use nonhuman primates (NHPs) or have used them in the past, are usually based on the
ostensible similarities of chimpanzees to humans. Of all NHPs, the common
chimpanzee (Pan troglodytes) and bonobo (“pygmy chimpanzee,” Pan paniscus) are
genetically most similar to humans. Though estimates initially suggested this
similarity was around 98.5 - 99%, more recent analyses suggest the figure may be in
the region of 95 - 96% (Britten 2002; Varki and Altheide 2005). Either way, these
figures suggest that chimpanzees would be the most likely non-human species to be of
assistance in the development of diagnostic or therapeutic techniques for combating
human diseases. NHPs are used in areas of research as diverse as hematology,
immunology, virology, pharmacology (Herodin et al., 2005), and neurotoxicology
(Evans 1990), to investigate potential bio-terrorism agents such as Ebola and Lassa
viruses, anthrax and the plague (Patterson and Carrion 2005), and even to examine the
physiological effects of the environment in space (Pesquies et al., 1978).
Chimpanzees specifically have recently been involved in research in most of these
areas, but chiefly in studies into acquired immunodeficiency syndrome (AIDS) and
hepatitis C virus (Herodin et al., 2005).
Research on captive chimpanzees remains controversial, however, with opponents
citing numerous and varied animal welfare, ethical, scientific and financial concerns
(Sauer 2000; Thew 2000). Because of these concerns, some form of scientific
evaluation and objective appraisal of the necessity and human benefits derived from
research on captive chimpanzees is imperative. Notably, captive chimpanzee research
must be regarded as a “special case;” most of the public, and indeed much of the
scientific community, agree that the associated ethical cost at the very least demands a
results-oriented pay-off in the form of substantial, tangible, human medical progress.
Determining the scientific justification for chimpanzee research is paramount: if it
exists, then concerns can be addressed and weighed against benefits. The argument to
end chimpanzee research may become too strong to be effectively countered, if
scientific justification is hard to come by other than in the form of speculative claims
emanating from individuals closely involved in it.
A first step in assessing the merits of research on captive chimpanzees is to obtain a
clear picture of the biomedical disciplines examined by such research. Some work has
already been done in this area: based on 184 grant abstracts filed in the Computer
Retrieval of Information on Scientific Projects (CRISP) database and 89 journal
articles cited in PubMed (the U.S. National Library of Medicine's premier
bibliographic database), Conlee et al. (Conlee et al., 2004) provided some initial
indications of the disciplines investigated by chimpanzee research within the U.S. In
addition, Carlsson et al. (Carlsson et al., 2004) surveyed 2,937 articles published in
2001 describing 4,411 NHP studies using over 41,000 animals worldwide, though
only a small minority of these were studies of chimpanzees.
Copyright © 2007. New England Anti-Vivisection Society
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Here we assess the utility of chimpanzee research in combating human disease, using
a two-phase approach: 1) we determined the frequency with which chimpanzee
research published in peer-reviewed journals was cited by papers describing human
prophylactic, diagnostic or therapeutic methods (using the Cochrane Collaboration’s
guidelines for systematic reviews (Higgins and Green 2005) where appropriate), and
2) we quantitatively and qualitatively assessed the nature and importance of the
contributions provided by the cited chimpanzee studies. The survey was limited to
major biomedical bibliographic databases likely to contain human medical papers,
and attention was focused on research on captive chimpanzees because such research
has raised the most concerns.
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METHODS
We searched three biomedical bibliographic databases for papers describing research
involving living chimpanzees or chimpanzee tissue from 1995 to 2004 inclusive:
CAB Abstracts, the most comprehensive bibliographic database covering the applied
life sciences, containing over 4.5 million records (Anonymous 2006a,b); EMBASE,
the Excerpta Medica database, which is a biomedical and pharmacological database
containing over 10 million records (Anonymous 2006c); and Medline, the premier
medical and allied health profession database, containing over 12 million records
(Anonymous 2006d). Jointly these databases included over 6,000 biomedical journals
and thousands of other scientific documents sourced from more than 140 countries.
Where appropriate, we also applied the Cochrane Collaboration’s guidelines for
systematic reviews (Higgins and Green 2005), applying many of their
recommendations including those regarding protocol development; data collection,
analysis and interpretation; and report content and structure.
All titles, abstracts, and associated fields were searched for “chimpanzee,” “bonobo,”
“Pan troglodytes,” and “Pan paniscus,” limiting the search to documents with
abstracts. These included:




Studies of captive chimpanzees;
Studies of biometric information taken from captive chimpanzees, such as
MRI scans;
Studies of fresh or preserved chimpanzee tissues, other than those specified
below.

They excluded:








Studies of free-living chimpanzees;
Veterinary case reports of the diagnosis, treatment or post-mortem
examination of naturally-ill chimpanzees, whether in captivity or not;
Genome studies (excluding those of experimentally infected chimpanzees);
Studies of skeletal anatomy (museum specimens were often used);
Studies of cell lines (although cell samples obtained from captive chimpanzees
were included);
Studies of chimpanzee blood where the source was not specified;
Secondary analyses of data obtained in primary studies.

From 749 chimpanzee studies that met the inclusion criteria, we randomly selected a
subset of 100 studies using the “Research Randomizer” random number generator
(www.randomizer.org). This was done for logistical reasons; performing a detailed
citation analysis for 749 studies is a mammoth undertaking. Four of these citing
papers were not available through the bibliographic databases used, and one
additional study was cited only by a paper for which no abstract was available. Our
analysis criteria (including a requirement for readily-accessible papers with published
abstracts) led to these studies being excluded from further consideration, leaving 95
chimpanzee studies in the analysis. This sample size represents a number exceeding
the sample size required to achieve statistical significance, based on the normal
Copyright © 2007. New England Anti-Vivisection Society
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approximation to the binomial distribution for a 95% confidence level with an error of
plus or minus 10%.
These 95 studies were examined to determine the frequency with which they were
cited by papers subsequently published in peer-reviewed journals indexed by the
named bibliographic databases, as of January 2006. The species and biomedical
disciplines that were the focus of these citing papers were also determined.
In particular, where abstracts of citing papers described prophylactic, diagnostic or
therapeutic methods with clear potential for combating human diseases, the full-text
of the citing articles (human subjects) was reviewed to determine the contribution of
the cited chimpanzee study to the development of the method described, in
comparison with other cited sources of knowledge. In each case, both the entire citing
and cited papers were thoroughly examined, related articles sought (via direct links
from literature databases and also via specific new database searches) to determine
how the method had progressed since publication of the citing paper, and (where
appropriate) clinical trial data obtained to assess the relevance and application of the
method to human clinical practice. The contribution of a cited chimpanzee study was
assessed by appraising the context of its citation, and by scanning all the references in
the citing paper to derive the main contributors to the findings reported by it.
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RESULTS
Using the specified search terms, 2400 abstracts were found dating up to 28th August
2005. Of these, 749 were studies of captive chimpanzees or chimpanzee tissue that
met our inclusion criteria.
We classified the areas of investigation of all 749 chimpanzee papers into several
categories as follows:
48.5% (363/749) of these were biological investigations, and 41.5% (311/749) were
virology experiments (Figure 1). Biological investigations comprised nine
disciplines, of which the most frequent were cognition/neuroanatomy/neurology
(36.6%, 133/363) and behavior/communication (20.7%, 75/363) (Figure 2).
Virological investigations involved 30 different types of virus, of which the most
frequent were hepatitis C virus (HCV) and human immunodeficiency virus (HIV),
each of which comprised 31.2% (97/311) of all virology experiments (Figure 3).

Figure 1: 2400 abstracts describing chimpanzee studies were found, dating from 1995 to 2004. Of
these, 749 were studies that met the inclusion criteria. 48.5% (363/749) were biological experiments,
and 41.5% (311/749) were virology experiments. A further 10% belonged to a variety of other
categories.
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Figure 2: Biological investigations constituted 48.5% of chimpanzee experiments that met the
inclusion criteria, performed between 1995 and 2004 inclusive. These were conducted in nine
disciplines, of which the most frequent were cognition/neuroanatomy/neurology (36.6%, 133/363) and
communication/communication (20.7%, 75/363).

Therapeutic investigations comprised 3.5% (26/749) of all chimpanzee experiments,
of which almost two-thirds (16/26) investigated the pharmacological properties of a
variety of compounds (Figure 4). Other investigations included the testing of surgical
techniques or prostheses, anesthesiology, and toxicology of compounds other than
pharmaceuticals. Parasitology experiments comprised 3.1% (23/749) of the total
(Figure 5). Eight parasitic species were examined, of which the most frequent were
the malaria protozoa Plasmodium falciparum and P. ovale (26.1%, 6/23), the
roundworm Onchocerca volvulus (21.7%, 5/23), and the flatworm Schistosoma
mansoni (17.4%, 4/23).
Other diseases and miscellaneous experiments combined comprised 3.5% (26/749) of
all chimpanzee experiments, of which the most frequent were investigations of
laboratory/husbandry techniques (42.3%, 11/26) and endotoxemia (30.1%, 8/26)
(Figure 6). Three radiation studies were performed, and four other diseases were
investigated: benign prostatic hyperplasia, Creutzfeldt-Jakob disease, gastrointestinal
bacteriology (Bacillus thuringiensis), and tuberculosis (Mycobacterium tuberculosis).
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Figure 3: Virological investigations constituted 41.5% of chimpanzee experiments that met the
inclusion criteria, performed between 1995 and 2004 inclusive. They were conducted in 30 disciplines,
of which the most frequent were hepatitis C virus (HCV) and human immunodeficiency virus (HIV),
each of which comprised 31.2% (97/311) of all virology experiments.
HCV = hepatitis C v, HIV = human immunodeficiency v, HBV = hepatitis B v, RSV = respiratory
syncytial v, HEV hepatitis E v, STLV = simian T-cell lymphotropic v, SIV = simian
immunodeficiency v, TTV = transfusion-transmitted v, FV = foamy v (human and simian FV), HAV =
hepatitis A v, GBV-B = a close relative of HCV affecting tamarins, HV = herpes v, IV = influenza v,
PIV = parainfluenza v, HCMV = human cytomegalovirus, HGV = hepatitis G v, HMPV = human
metapneumovirus, H/S TLV = human/simian T-cell leukemia v, LCV = lymphocryptoviruses, RV2 =
rhadinovirus (or gamma-2-herpesvirus) genogroup 2, VZV = varicella-zoster v, WMHBV = woolly
monkey hepatitis B v.

Citations of chimpanzee studies
Notably, 49.5% (47/95) of these chimpanzee studies were not cited by any subsequent
papers (Figure 7) (95% confidence interval for proportion of papers not cited in the
original population of 749 papers = [0.395-0.595]. In other words, if this sampling
was done repeatedly, one could be 95% certain that the proportion of chimpanzee
studies not cited by any subsequent papers would be between these values, i.e. 39.5%59.5%).
The remaining 48 chimpanzee experiments were cited by 143 papers for which
abstracts were available. Some of these citing papers focused on humans alone; others
did so in combination with other species, namely: bacteria (Escherichia coli); pigeons
(Columba livia); bottlenose dolphins (Tursiops truncatus); dogs (Canis familiaris);
Asian elephants (Elephas maximus); mice (natural or genetically-modified); pigs, and,
unsurprisingly, a large variety of primate species: African green monkeys
Copyright © 2007. New England Anti-Vivisection Society
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Figure 4: Therapeutic investigations comprised 3.5% (26/749) of all chimpanzee experiments, of
which 61.5% (16/26) investigated the pharmacological properties of various compounds. Other
investigations included the testing of surgical techniques or prostheses, anesthesiology and toxicology
experiments.

(Chlorocebus aethiops); chimpanzees (Pan troglodytes or Pan paniscus); common
marmosets (Callithrix jacchus); cotton top tamarins (Saguinus oedipus); cynomolgus
macaques (Macaca fascicularis); Japanese macaques (Macaca fuscata); rhesus
macaques (Macaca mulatta); squirrel monkeys (Saimiri sciureus); tufted capuchin
monkeys (Cebus apella); olive baboons (Papio anubis); orangutans (Pongo abelii and
Pongo pygmaeus) and western lowland gorillas (Gorilla gorilla gorilla).
A variety of biological disciplines were explored in these citing papers, with the
hepatitis and human immunodeficiency viruses (HIV) featuring most prominently.
Others included (in alphabetical order): asthma, autism, behavior, benign prostatic
hyperplasia, cancer, chronic obstructive pulmonary disease (COPD), coxsackievirus
B3, Epstein-Barr virus (EBV), genetic studies, human parainfluenza virus type 3,
immunology, Kawasaki disease, laboratory techniques (including gene expression
profiling and cDNA microarray interpretation), leukemia, malaria, neuroanatomy,
neurology, organ transplantation, pathology (clinical), psychology, respiratory
syncytial virus (RSV), rheumatoid arthritis (RA), rhinovirus colds, simian
immunodeficiency virus (SIV), systemic lupus erythematosus (SLE), surgical
techniques (cardiac allografts), toxicity (arsenic, transmissible spongiform
encephalopathies (TSE)), and non-specific virology.
In addition to the 49.5% of papers in our random sample that were not cited, 35.8%
(34/95) of those chimpanzee studies were cited only by papers (a total of 116) that did
Copyright © 2007. New England Anti-Vivisection Society
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not describe well-developed prophylactic, diagnostic or therapeutic methods for
combating human diseases (Figure 7).

Figure 5: Parasitology experiments comprised 3.1% (23/749) of all chimpanzee experiments. Eight
parasitic species were investigated, of which the most frequent were the malaria protozoa Plasmodium
falciparum and P. ovale (26.1%, 6/23), the roundworm Onchocerca volvulus (21.7%, 5/23), and the
flatworm Schistosoma mansoni (17.4%, 4/23).

Papers describing human prophylactic, diagnostic or
therapeutic methods
Only 14.7% (14/95) of our random sample of chimpanzee studies were cited by a total
of 27 papers that described human prophylactic, diagnostic or therapeutic methods. Of
these, 5 described diagnostic methods and 22 described prophylactic and/or
therapeutic methods for combating human diseases, which were either fully
developed for human use or in the latter stages of development at the time of
publication (Figure 7). Diseases examined in these citing papers included cancer
(non-specific), COPD, EBV, hepatitis viruses A through G (HAV through HGV),
hepatocellular carcinoma, HIV, malaria, organ transplant rejection, RSV, RA,
rhinovirus colds, SLE and TSE. 63.0% (17/27) of these human medical papers were
wide-ranging reviews of up to 300 studies, in which the cited chimpanzee study made
only a minor contribution – as discussed later.
Detailed reviews of each of the 27 papers citing the 14 chimpanzee papers from our
random sample (that had described human prophylactic, diagnostic or therapeutic
methods) were carried out, to determine the contribution of the chimpanzee studies to
the human prophylactic, diagnostic or therapeutic method described in the citing
paper. These can be found in the supplement to this paper; a summary of the papers
Copyright © 2007. New England Anti-Vivisection Society
All rights reserved.
www.releasechimps.org
617-523-6020

12

citing the chimpanzee studies from our random sample, and of the cited chimpanzee
studies, is provided in Table 1.

Figure 6: Other diseases and miscellaneous experiments comprised 3.5% (26/749) of all chimpanzee
experiments when combined, of which the most frequent were investigations of laboratory/husbandry
techniques (42.3%, 11/26) and endotoxemia (30.1%, 8/26). Three radiation studies were also
conducted, and four other diseases were investigated, namely benign prostatic hyperplasia, CreutzfeldtJakob disease, gastrointestinal bacteriology (Bacillus thuringiensis), and tuberculosis (Mycobacterium
tuberculosis).
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Figure 7: Citations of 95 randomly selected published chimpanzee studies. 49.5% (47/95) of these
papers had not been subsequently cited in the scientific literature; (95% confidence interval for
proportion of papers not cited in the original population of 749 papers = [0.395-0.595]). The remaining
48 chimpanzee experiments were cited by 143 papers. 35.8% (34/95) of these were cited only by 116
papers that did not describe well-developed prophylactic, diagnostic or therapeutic methods for
combating human diseases. Just 14.7% (14/95) of our random sample of chimpanzee studies described
human prophylactic, diagnostic or therapeutic methods, and these were cited by a total of 27 papers.
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TABLE 1
CITING PAPER
No.

Paper

Type

1

Tong & Stone (2003)

Review

2

Suzuki et al. (2001)

Research paper

3

Khanna et al. (1999)

Review

4

Koff (2002)

Review

5

Regev & Schiff (1999)

Review

6

McMahon et al.
(2005)

Research paper

7

Karayiannis (2003)

Review

8

Research paper

12

Hüssy et al. (1997)
Feld & Hoofnagle
(2005)
Nakano et al. (1999)
Worm & Wirnsberger
(2004)
Obriadina et al. (2002)

13

Kim & Wang (2003)

Review

9
10
11

14
15

Armbruster et al.
(2002)
Armbruster et al.
(2004)
Bardsley-Elliot &
Perry (2000)

CITED PAPER
Topic

Cancer (non-specific):
therapeutic
COPD: prophylactic
Epstein-Barr virus:
prophylactic
HAV & HBV:
prophylactic
Hepatitis viruses A-G:
prophylactic & therapeutic
HBV: prophylactic
HBV: prophylactic &
therapeutic
HCV: diagnostic

No. References

Paper

Times
Cited

155

Brams et al. (2001)

6

28

Huguenel et al. (1997)

6

112

Bertoni et al. (1998)

2

85

Ogata et al. (1999)

5

71

Mast et al. (1998)

13

38

Ogata et al. (1999)

5

300

Pancholi et al. (2001)

5

24

Wang et al. (1996)

8

Review

HCV: therapeutic

91

Bigger et al. (2001)

10

Research paper

HCV: therapeutic
HEV: prophylactic
methods
HEV: diagnostic
Hepatocellular carcinoma:
diagnostic
HIV: prophylactic &
therapeutic
HIV: prophylactic &
therapeutic
HIV: prophylactic &
therapeutic

26

Wang et al. (1996)

8

133

Mast et al. (1998)

13

32

Mast et al. (1998)

13

81

Bigger et al. (2001)

10

25

Conley et al. (1996)

10

27

Conley et al. (1996)

10

Review
Research paper

Research paper
Research paper

130

Grob et al. (1997)

2

17

Hone et al. (2002)

Review

HIV: prophylactic

108

Conley et al. (1996)

10

18

Sleasman &
Goodenow (2003)

Review

HIV: prophylactic &
therapeutic

93

Conley et al. (1996)

10

19

Yang et al. (1998)

Research paper

HIV: diagnostic

28

Conley et al. (1996)

10

16

Review

20

Gallo (2002)

Review

HIV: therapeutic

258

Goh et al. (1998)

10

21

Moore & Hill (2004)

Review

Malaria: prophylactic

104

Pancholi et al. (2001)

5

87

Newman et al. (2001)

2

150

Crowe et al. (1999)

1

15

Newman et al. (2001)

2

34

Huguenel et al. (1997)

6

77

Brams et al. (2001)

6

26

Cervenakova et al.
(2003)

1

22

Matthews et al. (2003)

Review

Organ transplant rejection:
therapeutic

23

Kneyber & Kimpen
(2002)

Review

RSV: prophylactic

24

Hepburn et al. (2003)

Research paper

25

Turner et al. (1999)

Research paper

26

Gescuk & Davis
(2002)

Review

27

Brown (2005)

Review

Rheumatoid arthritis:
therapeutic
Rhinoviral colds:
prophylactic
SLE: therapeutic
TSE: diagnostic

Table 1: The twenty-seven medical papers citing publications from our random sample of 95
chimpanzee studies. Relevant details of each citing paper are summarized, along with information
concerning the actual chimpanzee study cited in each case and the number of times these chimpanzee
studies had been cited in total, at the time of our analysis. COPD = chronic obstructive pulmonary
disease; HAV–HCV = hepatitis viruses A–C; HEV = hepatitis E virus; HIV = human
immunodeficiency virus; RSV = respiratory syncytial virus; SLE = systemic lupus erythematosus; TSE
= transmissible spongiform encephalopathy.
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DISCUSSION
Contributions made by chimpanzee studies
For a variety of reasons, the chimpanzee studies from our random sample were found
to be incidental to most of these human medical papers (Table 2).

TABLE 2
Reason for lack of
contribution of chimpanzee
study to human
prophylactic, diagnostic or
therapeutic method
Redundant (concurrent human
experiments/“confirmations” of
human data)
Method not developed further
(possibly due to
chimpanzee/human differences)
Chimpanzee study peripheral to
human method described
Historical citation with no direct
relevance
Inconsistent with data from
other NHP studies
Inconsistent with human data
Purely speculative in nature
May have helped establish need
for new diagnostic method but
did not contribute further to its
development.

Total number of reviews
in category (of 27)

Specific reviews in
category

14

1, 5, 8-14, 16, 20, 24, 25,
27

7

2, 22-27

7

3, 4, 6, 13, 15, 21, 25

3

2, 17, 19

3

7, 17, 26

2
2

18, 24
3, 14

1

12

Table 2: Reasons why the random sample of chimpanzee studies in our analysis did not
contribute to the human prophylactic, diagnostic or therapeutic methods described in papers
citing them. Each review detailed in this analysis fits into one or more of the eight categories shown.
The total number of reviews in each category is shown, along with the specific reviews as numbered in
the results section of this study. It should be noted, however, that due to the complex and overlapping
nature of the studies and these categories, this table could not be considered to be exhaustive and allinclusive.
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In fourteen cases (Reviews 1, 5, 8-14, 16, 20, 24, 25 and 27; see Supplement) the
chimpanzee studies appeared to be redundant, as humans or human sera were studied
concurrently, or because they only served to confirm observations previously made in
humans. In seven cases (Reviews 2 and 22-27) the method explored in the cited
chimpanzee study was not developed further, sometimes because later clinical trials in
humans failed to demonstrate safety or efficacy, contrary to positive results in
chimpanzees. In seven cases (Reviews 3, 4, 6, 13, 15, 21 and 25) the chimpanzee
study examined a disease or method peripheral to the prophylactic, diagnostic or
therapeutic method described. In three cases (Reviews 2, 17 and 19) the chimpanzee
study merely illustrated an historical finding, or was cited during historical
discussions of attempts to combat the disease in question. In three cases (Reviews 7,
17 and 26) chimpanzee studies yielded results inconsistent with data from other NHP
studies, while in two cases (Reviews 18 and 24) they yielded results inconsistent with
human data. In two cases (Reviews 3 and 14) the cited chimpanzee studies were
purely speculative in nature and had therefore not contributed to the concrete findings
of the citing papers. In the remaining case (Review 12) the chimpanzee study may
have helped establish the need for a new diagnostic method but did not contribute
further to its development.
Five chimpanzee studies were cited by multiple human medical papers. The paper by
Bigger et al. on the effects of HCV in chimpanzees (Bigger et al., 2001), for example,
was peripheral to Kim and Wang’s paper (Kim and Wang 2003) describing a
diagnostic method for the detection of HCC (Review 13), and served only to confirm
what had already been observed in earlier human studies cited by Feld and
Hoofnagle’s paper (Feld and Hoofnagle 2005) on therapeutic methods for combating
HCV (Review 9).
Conley et al.’s study (Conley et al., 1996) of the prophylactic use of hMAbs in
chimpanzees challenged with HIV-1 was also cited by five medical papers. In two
studies of prophylactic and therapeutic methods for combating HIV (Armbruster et
al., 2002; 2004), prior positive results in the cited chimpanzee study suggested a
potential field of further development with respect to hMAb choices used in
combination prophylactic and therapeutic regimes (Reviews 14 and 15). The cited
chimpanzee study did not, however, play an integral role in the citing studies, the
purpose of which was to examine the safety, immunogenicity and pharmacokinetics
of hMAb protocols in clinically healthy HIV-1-infected human volunteers. In papers
by Yang et al. (Yang et al., 1998) and Hone et al. (Hone et al., 2002) describing the
development of vaccines and a diagnostic method respectively for combating HIV,
the cited chimpanzee study served only to demonstrate that effective HIV antibodies
can indeed neutralize HIV in chimpanzees, to varying degrees, although conflicting
results were observed in six other NHP studies cited by Hone et al (Reviews 17 and
19). Other than through such peripheral means, the cited chimpanzee study did not
contribute to the development of these prophylactic and diagnostic methods. The
contribution of this study towards the development of prophylactic and therapeutic
methods for combating HIV reviewed by Sleasman et al. (Sleasman and Goodenow
2003) was similarly limited by inconsistency with other cited human data (Review
18).
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Mast et al.’s paper (Mast et al., 1998) describing the poor concordance, sensitivity
and variable efficiency of previously available HEV assays in chimpanzees,
particularly against different HEV strains, was cited by Regev et al.’s review (Regev
and Schiff 1999) of prophylactic and therapeutic options for combating HAV, HBV,
HCV, HEV, HGV and TTV (Review 5), as well as by Obriadina et al.’s paper
(Obriadina et al., 2002a) describing the development of a diagnostic technique for the
detection of HEV (Review 12). The chimpanzees in Mast’s study were used as both
positive and negative controls, though both were redundant for more relevant positive
and negative human controls in the form of human sera were available concurrently.
Additionally, one of Mast et al.’s key outcomes was the highly discrepant existing
HEV assay results from U.S. blood donors that were presumed HEV negative,
necessitating great caution when interpreting positive assay results. This outcome
relied exclusively on human results.
Newman et al.’s paper (Newman et al., 2001) demonstrating the safety and efficacy
of Keliximab, a primatized IgG1 anti-CD4 mAb in modulating T-cell receptor
responsiveness in chimpanzees, was cited by two medical papers. In Matthews et al.’s
review (Matthews et al., 2003) of therapeutic strategies designed to thwart organ
transplant rejection, it was hoped that the targeting of cell-surface receptors might
result in T-cell inactivation, thereby delaying allograft rejection because T-cell
activation is central to the inflammation and tissue damage that precedes it (Review
22). Hepburn et al. (Hepburn et al., 2003) also described a clinical trial of
Clenoliximab, an anti-CD4 mAb antibody proposed for the treatment of RA (Review
24). However, a later phase II human clinical trial of an analogue drug
(Zanolimumab) failed to demonstrate efficacy at combating the disease, resulting in
abandonment of the development of this drug for RA patients and casting doubts on
the efficacy of anti-CD4 mAbs in decreasing allograft rejection.
A paper describing chimpanzee studies of DNA-based vaccines (Pancholi et al.,
2001) was cited both by Karayiannis’ review of the prophylactic and therapeutic
options available for combating HBV (Karayiannis 2003) (Review 7), and by Moore
and Hill’s review of strategies for the development of a malaria vaccine (Moore and
Hill 2004) (Review 21). In the former case, inconsistency with other chimpanzee and
NHP results limited the utility of the cited chimpanzee study, while in the latter the
disease and vaccination strategies explored were too disparate from those investigated
in the cited chimpanzee study to accord it other than peripheral relevance.
Wang et al.’s study of the reactivity of humans and chimpanzees to various epitopes
of HCV H strain structural proteins (Wang et al., 1996) was cited by both Hüssy et
al.’s paper investigating a diagnostic method for HCV (Hüssy et al., 1997) (Review
8), and by Nakano et al.’s paper investigating therapeutic options for HCV (Nakano et
al., 1999) (Review 10). However, in both cases only the human outcomes within this
chimpanzee study contributed to the citing medical paper. In fact, the cited
chimpanzee study highlighted differences in the immune response of humans and
chimpanzees to HCV.
Several authors of human medical papers or cited chimpanzee studies identified
potential problems associated with attempts to extrapolate chimpanzee results to
human outcomes. For example, in their study of prophylactic methods for combating
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EBV, Khanna et al. (Khanna et al., 1999a) stated that, “It would be a mistake to
assume that experimental results obtained in these … primate models had direct
relevance to vaccine formulations that might offer protection against infectious
mononucleosis [one of the main targets for a vaccine].” In his review of prophylactic
methods for combating HAV and HBV, Koff (Koff 2002) described the cited
chimpanzee study as potentially complicating our understanding of escape viruses.
Wang et al. (Wang et al., 1996) identified key differences between the immune
response of humans and chimpanzees to HCV infection. When commenting on the
failure of a test drug to demonstrate efficacy at combating (T-cell dependent) RA in a
phase II clinical trial, despite prior efficacy of an analogue drug in modulating T-cell
receptor responsiveness in chimpanzees, Newman et al. (Newman et al., 2001) stated
that, “…results to date illustrate the profound difficulties in translating animal model
success to the clinical arena.” Development of this test drug for RA patients was
discontinued.

Sources contributing to human medical papers
Techniques featuring most frequently in the development of the prophylactic,
diagnostic or therapeutic methods described in the 27 medical papers detailed above
included in vitro studies, human clinical and epidemiological studies, molecular
assays and methods, and genomic studies. Methods featuring particularly prominently
included:


In vitro studies in at least 18 papers, utilizing for example: HeLa cells; human
adenoid explants; human respiratory epithelium (embryonic lung fibroblasts);
human T-cells; LCLs; and rodent cell lines. Several viral studies used E. coli
and baculoviruses in conjunction with Sf9 insect cells as vectors for viral
delivery and expression.



Human clinical and epidemiological studies in at least 15 and six papers,
respectively.



Molecular methods in at least eight studies, including: ELISA; immune
electron microscopy; PCR; radioimmunoassay; Western blot; and several
assays designed for the diagnosis of TSEs: a combination of competitive
antibody capture and CE; CDI; SIFT; and an immuno-PCR assay.



Chimpanzee studies were, of course, cited by all of the medical papers. Other
animal models were cited more prominently in five medical papers, including:
transgenic and natural mice, rats, hamsters, guinea pigs, goats, sheep, cows,
mink, woodchucks and NHPs (orangutans, baboons, cynomolgus macaques
and rhesus macaques). Several of these species were cited in only one paper
describing diagnostic methods for combating TSEs (Brown 2005), either as
sources or recipients of TSE-infected tissues.



Genomic techniques such as differential display, suppression subtractive
hybridization, representational difference analysis, serial analysis of gene
expression and microarray analysis (for example of viral genomes) featured
prominently in four medical papers.
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A detailed examination of the level of contribution of the various animal models other
than chimpanzees is beyond the remit of this paper. Citation of animal models other
than the chimpanzee in this review does not necessarily reflect a tangible contribution
to any study: it simply conveys its inclusion in a citing paper, the merit of which must
be addressed in the manner of similar citation analyses and systematic reviews that
have been conducted recently by various research groups (such as Pound et al. (2005),
Bailey et al. (2005), Knight et al (2006), Perel et al. (2006) and Hackam et al.
(2006)). Our evaluation was confined to the involvement of chimpanzees only.

Human utility of medical papers citing chimpanzee studies
Based purely on their appearance in the bibliographies of biomedical papers, research
on captive chimpanzees or chimpanzee tissues appears to have contributed towards a
large range of biomedical disciplines. But citations and involvement in research
programs are not a definitive indication of the necessity and value of a particular
approach or specific study or dataset, for which an in-depth assessment of each citing
paper and cited chimpanzee study is required. For example, papers may be cited due
to their negative contribution to an area of knowledge, for comparison to other
paradigms, and so on. Or, where citations of chimpanzee research arguably indicate a
positive contribution to the overall outcome, alternative methods may well have been
available and superior.
In our analysis, over three-quarters (21 of 27) of the medical papers did not describe
prophylactic, diagnostic or therapeutic methods for combating human diseases that
were sufficiently developed for routine human use and efficacious in a sizeable
proportion of human patients. Most of the putative vaccination strategies described
were far from completion and implementation: for example, one combination
chemotherapeutic protocol for HCV did not achieve sustained viral clearance in half
of chronically infected patients treated (Review 9), and when describing the
development of vaccines against RSV (which have been explored using a substantial
number of animal studies over many years), Kneyber et al. (Review 23) (Kneyber et
al., 2002) stated that “it will probably be at least another 5 to 10 years before any
routine vaccination against RSV becomes daily practice.”
In at least three cases (Reviews 2, 24 and 25), drugs being tested failed to progress to
the market following initial animal or human trials, indicating concerns over human
safety and/or efficacy. In one case (Review 8) the sensitivity of the diagnostic assay in
question was lower than that of the traditional assay, while in three other cases
(Reviews 12, 19 and 27) the diagnostic assays were not ready for routine medical use.
Several reports described vaccines in successful use for some time, such as the
combination HAV and HBV vaccine Twinrix (Review 4), and well-established
therapeutic methods such as the use of rIFN-Į for chronic HCV infection (Review 5),
Nevirapine in HIV patients (Review 16), and Cyclophosphamide for the treatment of
SLE (Review 26). In one case a single vaccine candidate for the prevention of HEV
that had passed a phase I clinical trial was being tested in a field trial in Nepal
(Review 11), though further tests were considered necessary to determine its longterm efficacy.
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CONCLUSIONS
Advocates of research on captive chimpanzees claim it has been of critical importance
during our struggles against major human diseases such as AIDS, hepatitis and cancer
(VandeBerg and Zola 2005) – even though it continues in only a small number of
nations, and indeed is banned or severely restricted in the UK, the Netherlands,
Sweden, New Zealand, Austria and Japan. A ban is also being considered by the
Swiss government as well as the European Union. Moreover, proponents insist that it
must remain a cornerstone of future biomedical research, and that it is an
indispensable facet of research that, if prohibited in the U.S., will see human beings
suffer and jeopardize or nullify possible future treatments or cures for human disease.
To be made with such conviction, these claims require strong evidence. It is generally
accepted that only a small fraction of scientific results, whatever the discipline and
however they were achieved, ever translate to human medical benefit or could ever be
remotely applicable to clinical practice. Nevertheless, that research is pursued for the
sake of knowledge itself, and also partly because we do not know how applicable any
area of investigation might be in the future. However, chimpanzee research is a
special case as testified to by not only public and scientific opinion, but also by
various policies and laws in the U.S. Research using chimpanzees has an ethical cost
way above biomedical research involving bacteria and yeast, for example: passage of
the CHIMP (Chimpanzee Health Improvement, Maintenance and Protection) Act in
the U.S. in 2000, as well as the many countries limiting the use of great apes,
acknowledges a different moral status for chimpanzees and raised the bar regarding
the ethical considerations that the scientific community (as well as the general public)
confers upon chimpanzees.
Both science and the public acknowledge that chimpanzees have varied and advanced
cognitive and emotional abilities; they can be taught human languages such as
American Sign Language and demonstrate complex nonverbal communication
patterns. They are capable of reasoned thought, abstraction, generalization, symbolic
representation and have a concept of self, and they exhibit a broad range of emotions
and experience mental as well as physical pain. Chimpanzees (as well as other great
apes) in captivity show a range of behavioral abnormalities and measurable signs of
distress (psychopathology), which can result from early separation of infants from
their mothers, sensory-motor deprivation or social isolation over prolonged periods of
time (Brüne et al., 2006).
Quite aside from these characteristics of chimpanzees that arguably make them
worthy of a human level of moral consideration, the question remains: Has
chimpanzee research made a positive contribution to human health to scientifically
justify their continued use in spite of the ethical objections of many? Or has that
contribution been limited or even negative? And, overall, has it expedited medical
progress or hindered it? If the net contribution of chimpanzee experiments to human
medicine has been negligible, or negative, or if there are current and nascent research
avenues that are more promising and relevant, then there is a human-based ethical
argument for it to end. For if species differences have led to confounding data, blind
alleys and false dawns for new human therapies, then humans too have suffered as a
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result of misleading data from experiments involving chimpanzees – both directly and
indirectly.
Proponents of chimpanzee research, however, claim that it is precisely the differences
that can make chimpanzees so useful. If biochemical differences can be identified and
used to elucidate why, for example, chimpanzees respond differently to HIV, hepatitis
viruses, the malaria parasite and so on, they argue that these can be used as a
foundation on which to build future research and target new drugs. There are two
responses: one is that the analysis of such differences does not have to involve
invasive research on captive chimpanzees, but can instead use biological samples
taken from chimpanzees at sanctuaries, during routine and necessary operative
procedures, physical examinations and/or post mortems. The second is that science
has the tools to elucidate the molecular differences between humans that vary in their
responses to infectious agents and diseases. Further, by minimizing extraneous
differences and maintaining such investigations in a human context, they promise to
deliver tangible results more precisely, accurately quickly and effectively.
Regardless of the findings of analyses such as this study, proponents of chimpanzee
research may point to their involvement in, for example, hepatitis B and C research in
a bid to demonstrate that not all chimpanzee experimentation has been of little or no
use. The argument of the necessity of their involvement in hepatitis research and the
development of vaccines is a fierce one with strong claims on both sides of the
debate, but is not relevant to this review. No matter the veracity of claims on either
side; this review seeks to examine the value of chimpanzee experimentation over
recent years in order to assess its utility prospectively, and determine if there is a
scientifically valid reason to support its continuation.
For both ethical and scientific reasons, there is widespread unease about captivechimpanzee research within the scientific and wider communities. The fact that
several countries highly active in sophisticated biomedical research have banned or
severely limited research and testing using great apes testifies to this: most recently,
in the UK, an independent inspector stated that a new primate research centre in
Cambridge should not be built, on the basis that the proposed research to take place
there could not be demonstrated to be in the national interest. In the Netherlands, the
last research establishment in Europe housing chimpanzees was closed, after the
Dutch minister for science announced that it was not scientifically necessary.
In summary, our review identified no studies of captive chimpanzees that made an
essential contribution, or, in a large majority of cases, a significant contribution of any
kind towards papers describing well-developed prophylactic, diagnostic or therapeutic
methods for combating human diseases, including major diseases such as AIDS,
cancer and hepatitis. At best, it has on occasion made a minor contribution to a small
number of research projects, though an assessment of the crucial nature of this input
and possible alternatives to the use of chimpanzees in each instance was not in the
scope of our analysis. Additionally, it seems that data from chimpanzee experiments
correlate with the human situation in only a small minority of cases. It therefore
follows that reliable extrapolation of such data to humans is impossible, even
potentially hazardous; statistically, it cannot be considered predictive of the human
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condition or response. Retrospective correlations are useless, once the human data are
known, and “confirmatory” studies in chimpanzees must be deemed similarly futile.
Far from augmenting biomedical research, chimpanzee experimentation appears to
have been largely incidental, peripheral, confounding, irrelevant, unreliable and has
consumed considerable research funding that would have been better targeted
elsewhere. We call upon regulatory and funding bodies to take these data into account
when considering the future of chimpanzees in research and testing, and likewise the
U.S. government when considering the permanent retirement of chimpanzees
currently held in U.S. laboratories and the status of the chimpanzee breeding
moratorium.
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